AstraZeneca, BMS Expand Development Of Diabetes Drug Dapagliflozin To Include Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - AstraZeneca K.K., a fully owned Japanese subsidiary of AstraZeneca, has announced plans to market type 2 diabetes treatment dapagliflozin jointly with Bristol-Meyers Squibb in Japan, a company spokesman said
You may also be interested in...
AstraZeneca Shares Its Recipe For Partnering Success In Asia
Just six months ago, century-old banks were closing their doors, job opportunities were dwindling, and the global economy faced a very uncertain future, but in Asia - particularly China - that situation is quickly turning around and companies need to prepare appropriately if they want tap into the region's potential, says AstraZeneca's Asia Pacific R&D VP Patrick Keohane
AstraZeneca Shares Its Recipe For Partnering Success In Asia
Just six months ago, century-old banks were closing their doors, job opportunities were dwindling, and the global economy faced a very uncertain future, but in Asia - particularly China - that situation is quickly turning around and companies need to prepare appropriately if they want tap into the region's potential, says AstraZeneca's Asia Pacific R&D VP Patrick Keohane
AstraZeneca Turns Gaze On Global Impact Of Diabetes Crisis
HONG KONG - If viral diseases were the scourge of the nineteenth and twentieth centuries, diseases born of more effective healthcare and wealth might represent the next threat. Prominent among them is diabetes, which causes about 5 percent of deaths around the world every year